Xilio Therapeutics (XLO) FCF Margin (2024 - 2026)

Xilio Therapeutics has disclosed FCF Margin across 3 years of filings, most recently posting 181.05% for Q1 2026.

• FCF Margin for Q1 2026 came in at 181.05%, down 116009.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 106.75% (down 33098.0% YoY), and the FY2025 annual result was 12.59%, up 27767.0% from the prior year.
• FCF Margin came in at 181.05% for Q1 2026 at Xilio Therapeutics, down from 15.29% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 979.04% in Q1 2025 to a low of 821.52% in Q4 2024.
• The 3-year median for FCF Margin is 136.23% (2025), against an average of 8.66%.
• Across the five-year window, FCF Margin surged 80623 bps in 2025 and sank 116009 bps in 2026, its largest moves.
• Xilio Therapeutics' FCF Margin stood at 821.52% in 2024, then soared by 98 bps to 15.29% in 2025, then sank by 1084 bps to 181.05% in 2026.
• The last three FCF Margin figures came in at 181.05% (Q1 2026), 15.29% (Q4 2025), and 91.76% (Q3 2025), per Business Quant data.